• Lexaria Bioscience Corp (NASDAQ: LEXX) announced additional findings from its human clinical study HYPER-H21-4 demonstrating a potentially novel mechanism of action of its DehydraTECH-processed cannabidiol capsule formulation in reducing blood pressure.

• Lexaria previously announced that the study's primary efficacy and safety objectives were successfully achieved, with resting BP significantly reduced in hypertensive patients and sustained over the full 5-weeks of dosing, with zero serious adverse events being reported throughout the study.

• Ongoing analyses of the study data have revealed modulation of a circulating compound called catestatin in the patients.

• Catestatin is a multifunctional peptide known to have inhibitory effects on the sympathetic nervous system in the pathophysiology of hypertension.

• These analyses revealed that administration of DehydraTECH-CBD resulted in a statistically significant reduction in average baseline serum catestatin concentrations of 13.50 ng/mL to just 9.65 ng/mL after five weeks of dosing, a drop of 28.5%.

• There were no statistically significant reductions in catestatin concentrations in the placebo group.

• As previously reported, mean arterial pressure also dropped significantly by 4.26 ± 1.26 mm/Hg following the five weeks of DehydraTECH-CBD dosing, and this reduction was not observed with placebo.

• The extent of change in catestatin serum levels showed a strong correlation with the reduction in blood pressure.

• Price Action: LEXX shares are down 0.81% at $2.99 on the last check Tuesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Lexaria Discovers Potential Novel Mechanism From Hypertension Study Of Processed CBD originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.